Proteomics secures underwriting - PIQ Options to raise $3.4m
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Proteomics launches PromarkerD
- Strategic alliance and investment in CPR Pharma Services
- PromarkerD diabetic kidney disease patent granted in Japan
- Appendix 4C - December 2017 Quarterly Report
- Proteomics joins major health study to target lung disease
Later from Proteomics International Laboratories
- Directors Exercise PIQ Options
- Conversion of 90% of Proteomics Options raises of $3m
- Underwriters take final $342,000 of Proteomics Options
- Europe PromarkerD patent granted for diabetic kidney disease
- Appendix 4C - March 2018 Quarterly Report
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories